Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | EEF2K | O00418 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17755077 | 0.83 | FFAR1 (0.56) | LMNATP53HTTFFAR1EEF2K | |
| SCHEMBL22993739 | 0.80 | CTSA (0.45) | MEN1KMT2A | |
| SCHEMBL19420118 | 0.80 | EEF2K (0.48) | FFAR1EEF2KMEN1KMT2ACYP2D6 | |
| SCHEMBL19420103 | 0.80 | EEF2K (0.48) | FFAR1EEF2KMEN1KMT2ACYP2D6 | |
| SCHEMBL10832271 | 0.80 | LMNA (0.53) | LMNATP53HTTMEN1KMT2A | |
| SCHEMBL8667654 | 0.78 | EEF2K (0.49) | LMNATP53HTTFFAR1EEF2K | |
| SCHEMBL18925051 | 0.78 | TP53 (0.55) | LMNATP53HTTMEN1KMT2A | |
| SCHEMBL3865104 | 0.77 | EEF2K (0.46) | FFAR1EEF2KTDP1 | |
| SCHEMBL5721001 | 0.77 | LMNA (0.50) | LMNATP53HTTEEF2KMEN1 | |
| SCHEMBL5721003 | 0.77 | LMNA (0.50) | LMNATP53HTTEEF2KMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324731-B2 | TXNIP-TRX complex inhibitors and methods of using the same | CITY OF HOPE (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200085800-A1 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | CITY OF HOPE | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324731-B2 | TXNIP-TRX complex inhibitors and methods of using the same | TXN, TXN2, TXNRD3 | LMNA 3153/4885TP53 3260/4885HTT 670/4885 |
| US-20200085800-A1 | TXNIP-TRX COMPLEX INHIBITORS AND METHODS OF USING THE SAME | TXN, TXN2, TXNRD3 | LMNA 3153/4885TP53 3260/4885HTT 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.